Stock Research for IBB

Featured Broker: Ally Invest

Get the due diligence for another stock.


IBB Stock Chart & Research Data

The IBB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IBB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


IBB Due diligence Resources & Stock Charts

The IBB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IBB Detailed Price Forecast - CNN Money CNN View IBB Detailed Summary - Google Finance
Yahoo View IBB Detailed Summary - Yahoo! Finance Zacks View IBB Stock Research & Analysis -

Stock Analysis

TradeIdeas View IBB Trends & Analysis - Trade-Ideas Barrons View IBB Major Holders - Barrons
NASDAQ View IBB Call Transcripts - NASDAQ Seeking View IBB Breaking News & Analysis - Seeking Alpha
Spotlight View IBB Annual Report - OTC Report View IBB OTC Short Report -
TradeKing View IBB Fundamentals - TradeKing Charts View IBB SEC Filings - Bar Chart
WSJ View Historical Prices for IBB - The WSJ Morningstar View Performance/Total Return for IBB - Morningstar
MarketWatch View the Analyst Estimates for IBB - MarketWatch CNBC View the Earnings History for IBB - CNBC
StockMarketWatch View the IBB Earnings - StockMarketWatch MacroAxis View IBB Buy or Sell Recommendations - MacroAxis
Bullish View the IBB Bullish Patterns - American Bulls Short Pains View IBB Short Pain Metrics -

Social Media Mentions

StockTwits View IBB Stock Mentions - StockTwits PennyStocks View IBB Stock Mentions - PennyStockTweets
Twitter View IBB Stock Mentions - Twitter Invest Hub View IBB Investment Forum News - Investor Hub
Yahoo View IBB Stock Mentions - Yahoo! Message Board Seeking Alpha View IBB Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for IBB - Insider Cow View Insider Transactions for IBB - Insider Cow
CNBC View IBB Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IBB - OTC Markets
Yahoo View Insider Transactions for IBB - Yahoo! Finance NASDAQ View Institutional Holdings for IBB - NASDAQ

Stock Charts

FinViz View IBB Stock Insight & Charts - StockCharts View IBB Investment Charts -
BarChart View IBB Stock Overview & Charts - BarChart Trading View View IBB User Generated Charts - Trading View

Latest Financial News for IBB

Gemphire Therapeutics stock plunges after trial halted due to 'unanticipated problems'
Posted on Friday August 10, 2018

Shares of Gemphire Therapeutics Inc. (gemp) plunged 17% toward a record low Friday after the biopharmaceutical company said a phase 2a trial of its treatment for non-alcoholic fatty liver disease in pediatric patients will be terminated, citing "unanticipated problems." The company said the data and safety monitoring board at Emory University overseeing the trial recommended the termination. Gemphire said data on the first three patients undergoing 12 weeks of treatment all experienced an increase in liver fat content, which was deemed an unexpected problem.

BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
Posted on Thursday August 09, 2018

BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.

How Ionis’s Q2 2018 Earnings Trended
Posted on Wednesday August 08, 2018

Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.

Ampio's stock plunges below $1 threshold after FDA comments on clinical trial
Posted on Wednesday August 08, 2018

Shares of Ampio Pharmaceuticals Inc. (ampe) plunged 69% in morning trade Wednesady, to fall back below the $1 threshold for the first time in 10 months, after the biopharmaceutical company said the Food and Drug Administration said a current trial for a treatment of osteoarthritis of the knee did not support a biologics license application (BLA). The FDA said the that as a single trial, the AP-003-A trial on its own does not appear to provide sufficient evidence of effectiveness to support a BLA. The FDA recommended an additional randomized trial.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.